JP2024514362A5 - - Google Patents

Info

Publication number
JP2024514362A5
JP2024514362A5 JP2023564654A JP2023564654A JP2024514362A5 JP 2024514362 A5 JP2024514362 A5 JP 2024514362A5 JP 2023564654 A JP2023564654 A JP 2023564654A JP 2023564654 A JP2023564654 A JP 2023564654A JP 2024514362 A5 JP2024514362 A5 JP 2024514362A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pain
composition according
approximately
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514362A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/053730 external-priority patent/WO2022224184A1/en
Publication of JP2024514362A publication Critical patent/JP2024514362A/ja
Publication of JP2024514362A5 publication Critical patent/JP2024514362A5/ja
Pending legal-status Critical Current

Links

JP2023564654A 2021-04-22 2022-04-21 慢性疼痛の処置のための経皮医薬製剤 Pending JP2024514362A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163177981P 2021-04-22 2021-04-22
US63/177,981 2021-04-22
PCT/IB2022/053730 WO2022224184A1 (en) 2021-04-22 2022-04-21 Transdermal pharmaceutical formulations for the treatment of chronic pain

Publications (2)

Publication Number Publication Date
JP2024514362A JP2024514362A (ja) 2024-04-01
JP2024514362A5 true JP2024514362A5 (cg-RX-API-DMAC7.html) 2025-04-28

Family

ID=83722736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564654A Pending JP2024514362A (ja) 2021-04-22 2022-04-21 慢性疼痛の処置のための経皮医薬製剤

Country Status (8)

Country Link
US (1) US20220347151A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326252A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024514362A (cg-RX-API-DMAC7.html)
CN (1) CN117545478A (cg-RX-API-DMAC7.html)
AU (1) AU2022260813A1 (cg-RX-API-DMAC7.html)
CA (1) CA3215685A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012483A (cg-RX-API-DMAC7.html)
WO (1) WO2022224184A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CN119896633A (zh) * 2025-01-17 2025-04-29 中国人民解放军空军军医大学 一种水凝胶冷敷贴及其制备的冷热敷贴套装和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990026792A (ko) * 1997-09-26 1999-04-15 김윤 디클로페낙 디에틸암모늄염을 함유한 매트릭스형 패취제제
WO2010127033A1 (en) * 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
MX2018004034A (es) * 2015-09-30 2018-12-19 Edward Hoag George Formulaciones topicas de analgesicos para alivio del dolor fabricacion y uso de los mismos.
US10525093B2 (en) * 2016-11-14 2020-01-07 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
US10966946B2 (en) * 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
IL292126B2 (en) * 2018-01-12 2025-04-01 Nutrae Llc Cannabinoid formulations are formulated for oral administration
CA3060926A1 (en) * 2018-09-06 2020-03-06 NuVessl, Inc. Method of using cannabinoids encapsulated in phospholipid carriers for transmucosal and transdermal administration
US20200197359A1 (en) * 2018-09-17 2020-06-25 Cody D. Freeze Cannabinoid and Terpene-Infused Topical Cream
CN118831076A (zh) * 2019-03-12 2024-10-25 Epm (Ip)公司 大麻素酸酯组合物及其用途
AU2020301119B2 (en) * 2019-06-28 2026-03-05 Nexzol Pharma, Inc. Transdermal formulations
CN114650809A (zh) * 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12016829B2 (en) * 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12186280B2 (en) * 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) * 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
JP2022551730A (ja) * 2019-10-14 2022-12-13 パイク セラピューティクス,インコーポレイテッド カンナビジオールの経皮送達
US20210346310A1 (en) * 2020-04-20 2021-11-11 Pike Therapeutics, Inc. Transdermal and/or topical, pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
US20220047541A1 (en) * 2020-08-17 2022-02-17 Pike Therapeutics, Inc. Pharmaceutical compositions and methods for treating parkinson's disease
MX2023006561A (es) * 2020-12-03 2023-07-06 Pike Therapeutics Inc Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer.

Similar Documents

Publication Publication Date Title
US10682357B2 (en) Treatment of erectile dysfunction and other indications
ES2962574T3 (es) Administración de agentes biológicamente activos utilizando disolventes volátiles hidrófobos
JP2023523155A5 (cg-RX-API-DMAC7.html)
AU2005251805B2 (en) Dermal peel-forming formulation
US20140004176A1 (en) Delivery of treatments transdermally for fungal infections and other indications
JP2016033168A (ja) Cox−2阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法
US20050187212A1 (en) Pharmaceutical composition for topical delivery of meloxicam
JP2022551730A5 (cg-RX-API-DMAC7.html)
CA2931144C (en) Anti-infective methods, compositions, and devices
US9289495B2 (en) Systems and methods for treatment of allergies and other indications
US20140010866A1 (en) Methods and systems for treatment of migraines and other indications
EP2968130A1 (en) Transdermal delivery of sildenafil and other phosphodiesterase type 5 inhibitors
JP2022550569A5 (cg-RX-API-DMAC7.html)
ES2197077T3 (es) Dispositivo transdermico que comprende farmacos anti-inflamatorios no esteroides incorporados en una matriz de un polimero acrilico adhesivo.
KR20070059758A (ko) 비스테로이드성 항염증제와 국소마취제를 포함하는 경피투여 조성물
JP2001072605A (ja) 経皮経粘膜吸収促進剤組成物
WO1992020376A1 (fr) Composition de promoteur de l'absorption percutanee et preparation externe pour l'administration de medicaments par voie percutanee
CN1449282A (zh) 烧伤的治疗
HK40039061B (en) Treatment of erectile dysfunction